RecruitingRecruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019 · Zenas BioPharma (USA), LLC
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis
About this study
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
* Screening Period: Up to 4 weeks.
* Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
* Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
* Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
* Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
Eligibility criteria
Inclusion Criteria:
1. 18 to 60 years of age, inclusive, at the time of signing the informed consent.
2. Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
3. Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
4. Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
5. Absence of clinical relapses for at least 24 months.
Exclusion Criteria:
1. The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
2. Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
3. History or current diagnosis of other neurological disorders that may mimic MS
4. History or current diagnosis of progressive multifocal leukoencephalopathy
5. Active, clinically significant viral, bacterial, or fungal infection
6. History of any other significant active medical condition
7. History of suicidal behavior within 6 months prior to Screening
8. Any prior history of malignancy
9. Patients on anticoagulation, or antiplatelet therapy
10. Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
11. Clinically significant laboratory abnormalities at Screening.
12. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
13. History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
Study design
Enrollment target: 990 participants
Allocation: randomized
Masking: quadruple
Age groups: adult
Timeline
Starts: 2026-03-23
Estimated completion: 2030-07
Last updated: 2026-11-18
Interventions
Drug: OrelabrutinibDrug: Placebo
Primary outcomes
- • Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks (Up to approximately 120 weeks)
Sponsor
Zenas BioPharma (USA), LLC · industry
Contacts & investigators
ContactPatient and Medical Information · contact · clinicaltrialsinfo@zenasbio.com · 833-269-4696
ContactPatient and Medical Information · contact · clinialtrialsinfo@zenasbio.com · 833-269-4696
All locations (98)
Arizona Neuroscience Research, LLCRecruiting
Phoenix, Arizona, United States
Perseverance Research Center, LLC (PRC)Recruiting
Scottsdale, Arizona, United States
Fullerton Neurology and Headache CenterRecruiting
Fullerton, California, United States
Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))Recruiting
Torrance, California, United States
Regina Berkovich MD, PhD IncRecruiting
West Hollywood, California, United States
SFM Clinical Research, LLCRecruiting
Boca Raton, Florida, United States
Nova Clinical Research, LLCRecruiting
Bradenton, Florida, United States
MS and Neuromuscular Center of ExcellenceRecruiting
Clearwater, Florida, United States
Neurology AssociatesRecruiting
Maitland, Florida, United States
Aqualane Clinical ResearchRecruiting
Naples, Florida, United States
University of South Florida Department of Neurology - MS DivisionRecruiting
Tampa, Florida, United States
Josephson Wallack Munshower Neurology, Pc Suite 225Recruiting
Indianapolis, Indiana, United States
University of Kansas Medical CenterRecruiting
Kansas City, Kansas, United States
KC Research Center, PA Neurology Research DeptRecruiting
Roeland Park, Kansas, United States
Boston Clinical TrialsWithdrawn
Boston, Massachusetts, United States
University of Massachusetts Memorial Medical CenterRecruiting
Worcester, Massachusetts, United States
Profound Research LLC at Oakland Neurology CenterRecruiting
Rochester Hills, Michigan, United States
Washington University School of MedicineRecruiting
St Louis, Missouri, United States
University Of New Mexico School Of MedicineRecruiting
Albuquerque, New Mexico, United States
Mount Sinai Medical CenterRecruiting
New York, New York, United States
The Ohio State University Wexner Medical Center (OSUWMC)Recruiting
Columbus, Ohio, United States
The Boster Center for Multiple SclerosisRecruiting
Columbus, Ohio, United States
OMRF Multiple Sclerosis Center of ExcellenceRecruiting
Oklahoma City, Oklahoma, United States
Premier NeurologyRecruiting
Greenville, South Carolina, United States
Neurology Clinic, P.C.Recruiting
Cordova, Tennessee, United States
Lone Star NeurologyRecruiting
San Antonio, Texas, United States
Texas Institute for Neurological Disorders - ShermanRecruiting
Sherman, Texas, United States
Southern Neurology Suite 2Recruiting
Kogarah, New South Wales, Australia
MS-Netwerk Limburg - RevalidatieRecruiting
Overpelt, Limburg, Belgium
DCC Neoclinic - SofiaRecruiting
Sovet, Belgium
Medical Center NevrocentrumRecruiting
Plovdiv, Plovdiv, Bulgaria
Medical Center Hera EOODRecruiting
Sofia, Sofia, Bulgaria
Diagnostic and Consultative Center ConvexRecruiting
Sofia, Sofia, Bulgaria
Medical Center Medica Plus OODRecruiting
Veliko Tarnovo, Tarnovo, Bulgaria
Avis Medica Hospital PlevenRecruiting
Pleven, Bulgaria
Klinicki Bolnicki Centar Zagreb-RebroRecruiting
Zagreb, Croatia
NEUROHK, s.r.o.Recruiting
Choceň, Czechia
Regional Hospital JihlavaRecruiting
Jihlava, Czechia
Astra clinic (Clinic4U)Recruiting
Tallinn, Harju, Estonia
CHU Brest Hospital CavaleRecruiting
Pordic, Brest, France
Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire CaremeauRecruiting
Nîmes, Gard, France
Centre Hospitalier Intercommunal (Chi) Poissy-Saint-Germain-En-Laye - Site De PoissyRecruiting
Poissy, Yveline, France
JSC CuratioRecruiting
Tbilisi, K'alak'i T'bilisi, Georgia
MD Georgia Staff Physician MediClub GeorgiaRecruiting
Tbilisi, Saburtalo, Georgia
LTD Pineo Medical EcosystemRecruiting
Tbilisi, Georgia
NNLE Jo Ann University HospitalRecruiting
Tbilisi, Georgia
Caucasus Medical Center LtdRecruiting
Tbilisi, Georgia
Raymann, LLCRecruiting
Tbilisi, Georgia
Zentrum fur klinische Forschung Dr.Scholl GmbHRecruiting
Bad Homburg, Hesse, Germany
Metropolitan General HospitalRecruiting
Cholargós, Athens, Greece
Errikos Dunant HospitalRecruiting
Athens, Attica, Greece
Valeomed Kft.Recruiting
Esztergom, Komarom-Esztergom Vamegye, Hungary
National Institute of Clinical NeurosciencesRecruiting
Budapest, Hungary
Komarom-Esztergom Varmegyei Szent Borbala KorhazRecruiting
Tatabánya, Hungary
University G. D'Annunzio of Chieti-PescaraRecruiting
Chieti, Chieti, Italy
IRCCS Istituto Neurologico Mediterraneo NeuromedRecruiting
Pozzilli, Isernia/Molise, Italy
Hospital of Lithuanian University of Health SciencesRecruiting
Kaunas, Kauno, Lithuania
Centrum Medyczne INTERCOR Sp. z o.o.Recruiting
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.Recruiting
Lublin, Lublin Voivodeship, Poland
NZOZ Neuromed M. i M. Nastaj Sp.PRecruiting
Lublin, Lublin Voivodeship, Poland
Malva TrialsRecruiting
Lublin, Lublin Voivodeship, Poland
Twoja Przychodnia Centrum Medyczne Nowa SólRecruiting
Nowa Sól, Lubusz Voivodeship, Poland
MTZ Clinical Researcz Powered by pratiaRecruiting
Warsaw, Mazovian, Poland
Nmedis sp. z o.o.Recruiting
Rzeszów, Rzeszów, Poland
Centrum Medyczne Pratia KatowiceRecruiting
Katowice, Silesian Voivodeship, Poland
MA-LEK Clinical Sp. z o.o.Recruiting
Katowice, Silesian Voivodeship, Poland
NZOZ Novo MedRecruiting
Katowice, Silesian Voivodeship, Poland
Neuro Medic ClinicRecruiting
Katowice, Upper Silesia, Poland
Twoja Przychodnia PCMRecruiting
Poznan, Wielkopolska, Poland
Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska LekarzyRecruiting
Poznan, Wielkopolska, Poland
Galen ClinicRecruiting
Lublin, Poland
Uniwersytecki Szpital Kliniczny w OlsztynieRecruiting
Olsztyn, Poland
Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki HertmanowskiejRecruiting
Plewiska, Poland
Prywatna Lecznica Certus Sp. z o.o.Recruiting
Poznan, Poland
EUROMEDIS Osrodek Badan KlinicznychRecruiting
Szczecin, Poland
Centrum Medyczne ProNeuro ŻoryRecruiting
Żory, Poland
Centrum Neurologii Krzysztof SelmajRecruiting
Lodz, Łódź Voivodeship, Poland
PRO SALUS Sp. z o.o. sp.k.Recruiting
Lodz, Łódź Voivodeship, Poland
Caribbean Center for Clinical ResearchRecruiting
Guaynabo, Puerto Rico
Spital Clinic CF ConstantaRecruiting
Constanța, Constanța County, Romania
Spitalul Municipal Sf. Doctori Cosma si Damian RadautiRecruiting
Radauti, Suceava, Romania
University Clinical Centre of SerbiaRecruiting
Belgrade, Belgrade, Serbia
University Clinical Centre of KragujevacRecruiting
Kragujevac, Serbia
Clinic of Neurology - Clinical Center NisRecruiting
Niš, Serbia
Complejo Hospitalario Universitario A CoruñaRecruiting
A Coruña, A Coruña, Spain
Hospital Clinic de BarcelonaRecruiting
Barcelona, Barcelona, Spain
Hospital Alvaro CunqueiroRecruiting
Vigo, Galicia, Spain
Hospital Gregorio MarañonRecruiting
Madrid, Madrid, Spain
Hospital Universitario Puerta de Hierro de MajadahondaRecruiting
Majadahonda, Madrid, Spain
Vithas Hospital Parque San AntonioRecruiting
Málaga, Málaga, Spain
Hospital Vithas Nisa SevillaRecruiting
Castilleja de la Cuesta, Seville, Spain
Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical HospitalRecruiting
Chernivtsi, Chernivtsi Oblast, Ukraine
CNE City Clinical Hospital #1 of Ivano-Frankivsk councilRecruiting
Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ukraine
Limited Liability Company Medical Center NeuroclinicRecruiting
Lviv, Lviv Oblast, Ukraine
Limited Liability Company "Neurofocus"Recruiting
Lviv, Lviv Oblast, Ukraine
Neuro GlobalRecruiting
Ivano-Frankivsk, Ukraine
Lviv National Medical University named after Danylo GalytskiyRecruiting
Lviv, Ukraine
Medical Clinical Investigational Center of Medical Center LLC Health ClinicRecruiting
Vinnytsia, Ukraine